| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -19.4 | -18.0 |
| Net income | -19.4 | -18.0 |
| EPS (diluted, $ a share) | $-0.28 | $-0.52 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PEPG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
PepGen Inc.: key numbers
- Share price
- $4.19Close, Nov 16
- Market cap
- $290M
- Shares outstanding
- 69.26MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from PepGen Inc.
All →PepGen Capital Raise of $125M
PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.
- Value
- $125M
PepGen Clinical Trial Data
PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in patients with myotonic dystrophy type 1. The data demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study, alongside functional improvements and a generally well-tolerated safety profile.
“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”
James McArthur, Ph.D., President and Chief Executive Officer